Lukacs, Regina
Schneider, Miklos
Nagy, Zoltan Zsolt
Sandor, Gabor Laszlo
Kaan, Kinga
Asztalos, Antonia
Enyedi, Lajos
Pek, Gyorgy
Barcsay, Gyorgy
Szabo, Antal
Borbandy, Agnes
Kovacs, Illes
Resch, Miklos Denes
Papp, Andras
Funding for this research was provided by:
Semmelweis University
Article History
Received: 11 January 2023
Accepted: 6 March 2023
First Online: 17 March 2023
Declarations
:
: Study participants were patients with neovascular AMD, subjects of two sites in Budapest, Hungary of the “Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (VIEW 2)” phase-3 multicenter, prospective, randomized, double blind clinical trial (ClinicalTrials.gov ID: NCT00637377). The trial was carried out in accordance with the tenets of the Declaration of Helsinki, with approval of respective institutional review boards of the participating centers.For the long-term follow-up after the VIEW 2 study, institutional review board approval was obtained for a retrospective analysis, the protocol was approved by the Regional Institutional Scientific and Research-Ethics Review Board of Semmelweis University, Budapest, Hungary (IRB approval nr: SE RKB 168/2022, ClinicalTrials.gov ID: NCT05678517). Written informed consent was obtained from each participant before enrollment and at the end of follow-up for the retrospective analysis.
: Not applicable.
: RL: Has received investigator fees from Bayer and Novartis, not related to this work.MS: Has received investigator fees from Allergan, Bayer, Novartis, and Roche, has served as an advisory board member for Novartis and Roche, and acted as consultant for AbbVie, not related to this work.GLS: No conflicting interests.KK: No conflicting interests.AA: Has received investigator fees from Bayer and Novartis, not related to this work.LE: Has received investigator fees from Bayer and Novartis, not related to this work.GP: Has received investigator fees from Bayer and Novartis, not related to this work.GB: Has received investigator fees from Bayer and Novartis, not related to this work.AS: Has received investigator fees from Bayer and Novartis, not related to this work.AB: Has received investigator fees from Bayer and Novartis, not related to this work.IK: Has received investigator fees from Bayer and Novartis, not related to this work.MDR: Has received investigator fees from Bayer and Novartis, not related to this work.ZZN: Has received investigator fees from Bayer and Novartis, not related to this work.AP: Has received investigator fees from Allergan, Bayer and Novartis, has served as an advisory board member for Bayer and Novartis.No other conflicting relationship relevant to this manuscript exists for any of the authors.